01.002 RWE KR JULY 2022 A 27-07-2022

Unique therapeutic options matched to patient characteristics identified by real-world evidence (RWE)

  • Interest and use of RWE in the pharmaceutical industry is expected to increase in the coming year, due to its role in regulatory approvals
  • However, studies have shown that accuracy levels of electronic data can be as vary from as low as 30% to as high as 90%
  • Where data is inaccurate, data enrichment will be required
  • Pharmaceutical companies will continue to design observational studies to reinforce efficacy arguments
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at